Sezary Syndrome: Clinical Trials

367 trials for Sezary Syndrome, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

231 completed, 67 terminated, 19 withdrawn, 17 recruiting. 151 Phase 1, 128 Phase 2, 44 Not applicable, 27 Phase 3, 3 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 1151Completed 109, Terminated 24, Withdrawn 5, Active not recruiting 3, Not yet recruiting 3, Recruiting 3, Unknown 3, Suspended 1
Phase 2128Completed 82, Terminated 23, Unknown 6, Active not recruiting 5, Withdrawn 5, Recruiting 4, Not yet recruiting 3
Not applicable44Completed 27, Terminated 11, Withdrawn 6
Phase 327Completed 17, Terminated 6, Unknown 3, Withdrawn 1
Early Phase 13Completed 2, Not yet recruiting 1
Phase 43Completed 2, Terminated 1

Follow Sezary Syndrome: new trials by email Literature Review of Sezary Syndrome trials Research Report on Sezary Syndrome

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Lenalidomide and Cosibelimab for the Treatment of Relapsed/Refractory Mycosis Fungoides or Sézary Syndrome
Biospecimen Collection, Computed Tomography, Cosibelimab - Recurrent Mycosis Fungoides, Recurrent Sezary Syndrome
Phase 1Not yet recruitingCity of Hope Medical Center142027-05-162026-11-09
Golidocitinib in Patients With Mycosis Fungoides/Sézary Syndrome and T-Cell Large Granular Lymphocytic Leukemia
Golidocitinib - Mycosis Fungoides/Sezary Syndrome, T-cell Large Granular Lymphocytic Leukemia
Phase 2Not yet recruitingWashington University School of Medicine242026-12-312026-11-05
A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors
MDSY-1240 - Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC)
Phase 1 / Phase 2Not yet recruitingMedsyn Biopharma, LLC752026-11-012026-10-27
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
KK2223 - T-cell NHL (PTCL or CTCL)
Phase 1RecruitingKyowa Kirin, Inc.722026-09-022026-09-30
Lymphocyte Phenotype of Autosomal Recessive Congenital Ichthyoses Mutated NIPAL4 (Nipal4-nEDD)
blood sampling - Sezary Syndrome, Ichthyosis, Lamellar
Not yet recruitingAssistance Publique - Hôpitaux de Paris102026-04-012026-03-17
Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma
Aclarubicin, Cyclophosphamide, Vincristine - Cutaneous T-Cell Lymphoma Refractory, Cutaneous T-Cell Lymphoma, Relapsed
Phase 1 / Phase 2Not yet recruitingShanghai Jiao Tong University School of Medicine372026-03-302026-04-17
A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL)
DT-7012 - Cutaneous T Cell Lymphoma (CTCL), Mycosis Fungoides
Early Phase 1Not yet recruitingAssistance Publique - Hôpitaux de Paris302026-01-012025-10-09
Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result Surveillance
Poteligeo 20mg - Mycosis Fungoides, Sezary Syndrome
RecruitingKyowa Kirin Co., Ltd.152025-05-022026-11-03
A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
PTX-100 - CTCL
Phase 2RecruitingPrescient Therapeutics, Ltd.1152025-03-282026-09-09
Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma
Cutaneous T Cell Lymphoma, Cutaneous T-Cell Lymphoma/Mycosis Fungoides
RecruitingFondazione Italiana Linfomi - ETS4002025-02-272025-12-02
A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab
Non-Interventional Study - Recurrent Mycosis Fungoides, Recurrent Sezary Syndrome
RecruitingCity of Hope Medical Center1002024-12-062026-11-04
Evaluation of the KIR3DL2 Marker in Flow Cytometry for Sézary Syndrome Diagnosis, Therapeutic Response and Residual Disease: a Prospective and Multicenter Study
Follow-up - Mycosis Fungoides/Sezary Syndrome, Cutaneous T Cell Lymphoma
Not yet recruitingAssistance Publique - Hôpitaux de Paris4602024-11-012024-10-21
Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma
Cutaneous T Cell Lymphoma, Cutaneous T-Cell Lymphoma/Mycosis Fungoides
CompletedFondazione Italiana Linfomi - ETS1002024-06-062026-06-01
A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell Lymphoma
molecular subtype based treatment - Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Cutaneous T Cell Lymphoma
RecruitingPeking University First Hospital1002024-05-092024-05-31
Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome
Tulmimetostat - Mycosis Fungoides, Sezary Syndrome
Phase 1Active not recruitingWashington University School of Medicine242024-01-092026-09-16
Novel Flow-cytometry Approaches to Improve the Detection of Tumor Cells in CTCL
Detection and quantitation of (blood) tumor cells in patients with mycosis fungoides (MF) / Sézary syndrome (SS). - Cutaneous T-Cell Lymphoma
RecruitingInstituto de Investigación Biomédica de Salamanca1002024-01-012025-05-01
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
Fenretinide - T-cell Lymphoma, Cutaneous/Peripheral T-Cell Lymphoma
Phase 1RecruitingSciTech Development, Inc.462023-12-182026-10-05
Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies
WU-CART-007 - T-Cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia
Phase 1SuspendedWashington University School of Medicine62023-10-102026-07-21
A Registry for People With T-cell Lymphoma
Optional Blood Sample and Nail Sample - T-cell Lymphoma, NK-Cell Lymphoma
RecruitingMemorial Sloan Kettering Cancer Center10002023-07-272026-05-20
Ritlecitinib in CTCL
Ritlecitinib - CTCL, Mycosis Fungoides
Phase 2TerminatedIcahn School of Medicine at Mount Sinai72023-05-172025-07-18

Showing 20 of 367. Sign in to see all of them.

Narrower conditions

Mycosis Fungoides (355)  ·  Lymphoma, T-Cell, Cutaneous (331)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (239)  ·  Lymphoma, Follicular (238)  ·  Lymphoma, Large B-Cell, Diffuse (237)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (234)  ·  Lymphoma, B-Cell, Marginal Zone (233)  ·  Lymphoma, Mantle-Cell (233)  ·  Lymphoma, Non-Hodgkin (228)  ·  Burkitt Lymphoma (226)  ·  Hodgkin Disease (218)  ·  Lymphoma, Large-Cell, Immunoblastic (216)  ·  Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (183)  ·  Lymphoma, Large-Cell, Anaplastic (181)

Broader conditions

Hemic and Lymphatic Diseases (367)  ·  Neoplasms by Histologic Type (367)  ·  Immunoproliferative Disorders (366)  ·  Lymphatic Diseases (366)  ·  Immune System Diseases (365)  ·  Lymphoma, T-Cell (351)  ·  Lymphoproliferative Disorders (337)  ·  Neoplasms (329)  ·  Hematologic Diseases (258)  ·  Leukemia, Lymphoid (257)  ·  Pathological Conditions, Signs and Symptoms (253)  ·  Pathologic Processes (251)  ·  Disease Attributes (249)  ·  Lymphoma, B-Cell (245)  ·  Chronic Disease (239)

Interventions

Peripheral Blood Stem Cell Transplantation (39)  ·  fludarabine phosphate (36)  ·  Cyclophosphamide (31)  ·  Mycophenolic Acid (28)  ·  Cyclosporine (25)  ·  Whole-Body Irradiation (24)  ·  Tacrolimus (22)  ·  Antilymphocyte Serum (18)  ·  Busulfan (18)  ·  Methotrexate (16)  ·  Radiotherapy (16)  ·  Filgrastim (14)  ·  Flow Cytometry (14)  ·  Etoposide (13)  ·  Lenalidomide (11)

Sponsors

National Cancer Institute (NCI) (48)  ·  Fred Hutchinson Cancer Center (32)  ·  City of Hope Medical Center (17)  ·  Northwestern University (17)  ·  Mayo Clinic (13)  ·  Case Comprehensive Cancer Center (12)  ·  Memorial Sloan Kettering Cancer Center (12)  ·  European Organisation for Research and Treatment of Cancer - EORTC (11)  ·  National Institutes of Health Clinical Center (CC) (10)  ·  Jonsson Comprehensive Cancer Center (8)  ·  Roswell Park Cancer Institute (7)  ·  Vanderbilt-Ingram Cancer Center (7)  ·  Wake Forest University Health Sciences (7)  ·  M.D. Anderson Cancer Center (6)  ·  UNC Lineberger Comprehensive Cancer Center (6)

Countries

United States (308)  ·  Italy (25)  ·  Germany (21)  ·  France (17)  ·  Switzerland (16)  ·  United Kingdom (15)  ·  Spain (14)  ·  Canada (11)  ·  Belgium (10)  ·  Austria (8)  ·  Australia (7)  ·  Netherlands (6)  ·  Israel (4)  ·  Poland (4)  ·  South Korea (4)

Top investigators

Timothy M. Kuzel, MD (5)  ·  Brenda Sandmaier (4)  ·  David Maloney (4)  ·  Roger Strair, MD, PhD (4)  ·  Shivaani Kummar, MD (4)  ·  Ajay Gopal (3)  ·  Barbara Pro, MD (3)  ·  David G. Savage, MD (3)  ·  Kyoo H. Lee, MD (3)  ·  Larisa J. Geskin, M.D. (3)  ·  Paul Martin (3)  ·  Thomas E. Witzig, MD (3)  ·  Abhinav Deol, M.D. (2)  ·  Alex Shalaurov, MD, PhD (2)  ·  Alison Moskowitz, MD (2)

Results publications

PMID 32632956, PMID 32499241, PMID 23770157, PMID 33883258, PMID 10552943, PMID 10764422, PMID 11231324, PMID 11410496, PMID 11675364, PMID 11895901, PMID 12525530, PMID 12543862, PMID 14630685, PMID 15107815, PMID 15459300, PMID 16135477, PMID 16148284, PMID 16710026, PMID 17020988, PMID 17119113, PMID 17397698, PMID 17515522, PMID 17854367, PMID 18327587, PMID 18463792, PMID 18698002, PMID 19170225, PMID 19199905, PMID 19451403, PMID 19789320, PMID 19826128, PMID 19841031, PMID 19900571, PMID 20142598, PMID 20166206, PMID 20229590, PMID 21135857, PMID 21247755, PMID 21355097, PMID 21498721, PMID 21715313, PMID 21719601, PMID 22259028, PMID 22480131, PMID 22924950, PMID 22981498, PMID 23045580, PMID 23256542, PMID 23358983, PMID 23393050

NIH funding

P30CA015704 (15), P30CA033572 (12), P30CA015083 (9), P30CA043703 (8), P30CA072720 (7), P30CA068485 (6), P01CA018029 (5), P30CA016086 (4), P30CA016672 (4), P30CA022453 (4), P30CA060553 (4), U01CA062491 (4), U01CA062502 (4), U01CA076576 (4), U01CA099168 (4)